This is a working overview of synthetic peptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-21. Anything still debated is marked as such rather than presented as settled.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
=== Canada === Under the regulation of the Canadian Food Inspection Agency, manufacturers can produce blue cheese with a maximum of 47 percent moisture and minimum of 27 percent milk fat. Salt is allowed to be used as a preservative; however, the amount of the salt or combination of salts shall not exceed 200 parts per million of milk and milk products used to make the cheese. The Canadian Food Inspection Agency does not limit the use of bacterial cultures to aid further ripening and flavoring preparations other than cheese flavoring.
Health can play a central role in how people live their lives, reflecting the overall condition in which an organism functions properly, both physically and mentally. Good physical health is associated with high energy and the ability to perform everyday activities. Physical illnesses and disabilities can negatively impact well-being by causing pain, limiting mobility, and reducing the capacity to engage in enjoyable or necessary activities. Good mental health is a state of internal equilibrium in which mental capacities function as they should. Mental disorders are associated with some form of psychological impairment: they typically disrupt the equilibrium by causing distress and may limit the activities a person can engage in. Discrimination can amplify the negative effects of socially stigmatized illnesses and disabilities. Despite its general impact, health does not fully determine happiness, and some individuals affected by severe illnesses and disabilities report high levels of subjective well-being. The availability of healthcare services can mitigate negative effects by providing treatments to restore health or manage and alleviate symptoms. Similarly, adopting a healthy lifestyle, like regular physical activity and a balanced diet, is associated with long-term benefits to well-being.
=== Exploration === In 1497 Bristol was the starting point for John Cabot's voyage of exploration to North America. For many years Bristol merchants had bought freeze-dried cod, called stockfish, from Iceland for consumption in England. However, the Hanseatic League, which was trying to control North Atlantic trade at this time, sought to cut off supplies to English merchants. It has often been suggested that this drove Bristol's merchants to look West for new sources of cod fish. On the other hand, while Bristol merchants did largely abandon Iceland in the late-15th century, Hull merchants continued to trade there. Moreover, recent research has shown that England's fisheries off Iceland actually grew significantly from the 1490s, albeit the centre for this activity shifted from Bristol to East Anglia. This makes it hard to sustain the argument that Bristol merchants were somehow 'pushed out' of Iceland. In 1481 two local men, Thomas Croft and John Jay, sent off ships looking for the mythical island of Hy-Brasil. There was no mention of the island being discovered but Croft was prosecuted for illegal exports of salt, on the grounds that, as a customs officer, he should not have engaged in trade. Professor David Beers Quinn, whose theories form the basis for a variety of popular histories, suggested that the explorers may have discovered the Grand Banks off Newfoundland, waters rich in cod. John Cabot was sponsored by Henry VII on his voyage in 1497, looking for a new route to the Orient.
Insulin is the hormone that is made by the body that controls the cell intake of glucose. Normally, the pancreas produces insulin in response to high glucose levels in the body to bring the blood glucose levels down. For those with type 1 diabetes, there will always be a need for insulin injections throughout their life, as the pancreatic beta cells are not capable of producing sufficient insulin. Insulin can not be taken orally because insulin is a hormone and is destroyed by the digestive tract. Insulin can be injected by several methods, including a hypodermic needle, jet injector, or insulin pump. There is also inhaled insulin that can be used in adults with diabetes. There are several types of insulin that are commonly used in medical practice, with varying times of onset and duration of action. These include:
Sources: en.wikipedia.org
Scattering data is usually represented in terms of the so-called excess Rayleigh ratio defined as the Rayleigh ratio of the solution or single particle event from which is subtracted the Rayleigh ratio of the carrier fluid itself and other background contributions, if any. The Rayleigh Ratio measured at a detector lying at an angle θ and subtending a solid angle ΔΩ is defined as the intensity of light per unit solid angle per unit incident intensity, I0, per unit illuminated scattering volume ΔV. The scattering volume ΔV from which scattered light reaches the detector is determined by the detector's field of view generally restricted by apertures, lenses and stops. Consider now a MALS measurement made in a plane from a suspension of N identical particles/molecules per ml illuminated by a fine beam of light produced by a laser. Assuming that the light is polarized perpendicular to the plane of the detectors. The scattered light intensity measured by the detector at angle θ in excess of that scattered by the suspending fluid would be
=== Nuclear magnetic resonance spectroscopy === Metal carbonyls are often characterized by 13C NMR spectroscopy. To improve the sensitivity of this technique, complexes are often enriched with 13CO. Typical chemical shift range for terminally bound ligands is 150 to 220 ppm. Bridging ligands resonate between 230 and 280 ppm. The 13C signals shift toward higher fields with an increasing atomic number of the central metal. NMR spectroscopy can be used for experimental determination of the fluxionality. The activation energy of ligand exchange processes can be determined by the temperature dependence of the line broadening.
Modified atmosphere/modified humidity (MA/MH) packaging is a technology used to preserve the quality of fresh produce so that it can be sold to markets far away from where it is grown, extend the marketing period, and to help suppliers reduce food waste within the cold chain. Commercial examples of MA/MH include sea freight of Galia and cantaloupe melons from Central and South America to Europe (a 21-day journey) and North America (a 7-day journey); transport of white asparagus from fields in Peru to markets in Western Europe (a 20-day journey by land and sea); and trucking of cherries from orchards in Turkey to supermarkets in the UK (a 7-day journey).
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.